



*Better Health, Brighter Future*

# Financial Results for FY2015

## DATA BOOK

**Takeda Pharmaceutical Company Limited (TSE code 4502)**

**Contact: Global Finance, IR**

TEL: +81-3-3278-2306

<http://www.takeda.com/>

**Quarterly Announcements / Presentations**

<http://www.takeda.com/investor-information/results/>

---

## Contents


---

I. Overview of Takeda group	1
■ Number of subsidiaries and affiliates by business segment	
II. Financial Results	
1. Financial highlights	2
2. Consolidated Statements of Income	3
3. Revenue / Product Sales	4-6
◆ Revenue by Regions	
◆ Ethical Drugs Revenue [Consolidated]	
◆ Ethical Drugs Revenue [Emerging Markets]	
◆ Ethical Drugs: Global major products' sales	
◆ Ethical Drugs: US major products' sales (in US\$)	
◆ Ethical Drugs: Japan major products' sales	
◆ Consumer Healthcare: Major products' sales	
4. Consolidated Statement of Financial Position	7-8
5. Consolidated Statement of Cash Flows	8
6. Segment Information	9
7. Capital expenditure, depreciation and amortization and impairment losses	9
8. Number of employees	10
9. Shareholders	11
10. Financial ratios	12
III. Pipeline	
1. Development Activities	13-17
■ Oncology	
■ Gastroenterology	
■ CNS	
■ Vaccines	
■ Specialty CV	
■ Others	
■ Recent progress in stage	
■ Discontinued projects	
■ Revised collaboration agreement	
■ Clinical study protocol summaries	
2. Research Activities	18
■ Main joint research activities	

---

# I. Overview of Takeda group

The Takeda Group consists of 151 companies, including the parent company submitting these consolidated financial statements, 135 consolidated subsidiaries (including partnership) and 15 affiliates accounted for by the equity method. The following chart shows the main business areas of the Takeda Group, the position of the companies that make up the Group within their respective areas of business, and relationships with each business segment.



## II. Financial Results

### 1. Financial highlights (more detail will be available in Page 3 and onward)

<b>Consolidated operating results (Billion JPY)</b>	FY13	FY14	FY15	vs. FY14	increase/ decrease	FY16 Forecasts
Revenue	1,691.7	1,777.8	1,807.4	29.6	1.7%	1,720.0
Overseas revenue	957.8	1,065.0	1,119.3	54.3	5.1%	1,100.0
<% of Revenue>	<56.6%>	<59.9%>	<61.9%>	<2.0pt>		<64.0%>
Revenue of ethical drugs segment	1,529.1	1,614.5	1,648.7	34.2	2.1%	1,560.0
R&D expenses *1	341.6	352.9	345.9	-7.0	-2.0%	325.0
<% of Revenue>	<20.2%>	<19.9%>	<19.1%>	<-0.7pt>		<18.9%>
Operating profit	139.3	-129.3	130.8	260.1	-	135.0
<% of Revenue>	<8.2%>	<Δ7.3%>	<7.2%>	<14.5pt>		<7.8%>
Profit before income taxes	158.9	-145.4	120.5	266.0	-	132.5
<% of Revenue>	<9.4%>	<Δ8.2%>	<6.7%>	<14.8pt>		<7.7%>
Net profit for the year	109.6	-143.0	83.5	226.5	-	
<% of Revenue>	<6.5%>	<Δ8.0%>	<4.6%>	<12.7pt>		
Profit attributable to owners of the Company	106.7	-145.8	80.2	225.9	-	88.0
<% of Revenue>	<6.3%>	<Δ8.2%>	<4.4%>	<12.6pt>		<5.1%>
Core earnings *2	314.2	288.3	292.4	4.1	1.4%	
<% of Revenue>	<18.6%>	<16.2%>	<16.2%>	<-0.0pt>		

\*1 Because of starting the new organizational structure and changing managerial accounting method from FY15, allocation accounts for some expenses have changed. For the purpose of compare FY14 expenses with the FY15 expenses under the same basis (underlying), amounts roughly estimated for this change are adjusted in FY14.

\*2 Profit from regular business calculated by deducting any temporary factors such as impacts from business combination accounting and from amortization/impairment loss of intangible assets etc., from operating profit.

<b>Consolidated financial position (Billion JPY)</b>	FY13 End	FY14 End	FY15 End	vs. FY14 End
Total assets	4,569.1	4,296.2	3,824.1	-472.1
Total liabilities	2,028.5	2,090.0	1,812.9	-277.1
Total equity	2,540.6	2,206.2	2,011.2	-195.0
Equity attributable to owners of the Company	2,470.7	2,137.0	1,948.7	-188.4
Ratio of equity attributable to owners of the Company to total assets	54.1%	49.7%	51.0%	1.2pt

<b>Shares</b>	FY13 End	FY14 End	FY15 End
Number of shares outstanding (1,000)	789,681	789,924	790,284
Treasury stock (1,000)	213	4,032	6,745
Stock price at year-end (JPY)	4,892	5,999	5,136
Total market value (Billion JPY)	3,863.1	4,738.8	4,058.9

<b>ROE•EPS•Dividend (JPY)</b>	FY13	FY14	FY15	vs. FY14
Return on equity attributable to owners of the Company	4.5%	-6.3%	3.9%	-
Basic earnings per share	135.10	-185.37	102.26	-
Annual dividends per share	180.00	180.00	180.00	-
Dividend pay-out ratio	133.2%	-	176.0%	-

<b>Exchange rate(JPY)</b>	FY13	FY14	FY15	FY16 Assumptions
US\$ Average (Apr.-Mar.)	100	109	121	110
Euro Average (Apr.-Mar.)	133	139	132	125

## 2. Consolidated Statement of Income

	FY13	FY14	FY15	vs. FY14	increase/ decrease	(Billions of Yen) FY16 Forecasts
Revenue	1,691.7	1,777.8	1,807.4	29.6	1.7%	1,720.0
Royalty income and service income	86.3	87.5	56.5	-31.1	-35.5%	
Cost of sales *1	490.3	528.1	535.4	7.3	1.4%	
<% of revenue>	<29.0%>	<29.7%>	<29.6%>	<-0.1pt>		
Gross Profit	1,201.4	1,249.8	1,272.0	22.2	1.8%	
<% of revenue>	<71.0%>	<70.3%>	<70.4%>	<0.1pt>		
SG&A expenses *1	556.2	634.7	650.8	16.1	2.5%	
<% of revenue>	<32.9%>	<35.7%>	<36.0%>	<0.3pt>		
Sales and Marketing expenses		436.6	460.6	24.0	5.5%	
General Administrative expenses		198.1	190.2	-7.9	-4.0%	
R&D expenses *1	341.6	352.9	345.9	-7.0	-2.0%	325.0
<% of revenue>	<20.2%>	<19.9%>	<19.1%>	<-0.7pt>		<18.9%>
Amortization and impairment losses on intangible assets associated with products	143.2	176.4	125.1	-51.3	-29.1%	140.0
Other operating income	23.9	107.2	25.1	-82.1	-76.6%	
Government grant income	2.6	3.1	3.7	0.6	18.6%	
Rental income	4.3	3.9	3.4	-0.5	-11.6%	
Gains on sales of assets held for sale	6.6	32.8	0.1	-32.8	-99.8%	
Royalty income on transfer of operations	4.7	6.5	4.9	-1.6	-24.4%	
Others *2	5.6	60.8	12.9	-47.9	-78.7%	
Other operating expenses	45.0	322.2	44.4	-277.8	-86.2%	
Expenses directly attributable to rental income	5.0	2.2	5.0	2.7	121.6%	
Donations and contributions	3.2	1.5	2.4	1.0	64.0%	
Restructuring expenses *3	21.7	31.2	25.8	-5.4	-17.4%	
Loss on Actos litigation	-	274.1	-	-274.1	-100.0%	
Others	15.1	13.2	11.2	-2.0	-15.0%	
Operating profit	139.3	-129.3	130.8	260.1	-	135.0
<% of revenue>	<8.2%>	<-7.3%>	<7.2%>	<14.5pt>		<7.8%>
Financial income	49.3	15.4	21.6	6.3	40.9%	
Interest income	1.4	2.3	2.3	0.0	0.1%	
Dividends income	3.3	3.3	3.3	0.1	2.0%	
Gains on sales of available-for-sale financial assets	40.5	8.9	15.1	6.2	69.3%	
Foreign exchange gains including gains on valuation of derivatives	4.1	-	-	-	-	
Interest on tax refund	-	-	-	-	-	
Others	0.0	0.9	0.9	0.1	6.6%	
Financial expenses	30.7	32.9	31.9	-0.9	-2.9%	
Interest expenses	4.9	5.8	5.3	-0.5	-9.1%	
Fair value adjustments of contingent considerations	11.0	16.2	7.6	-8.6	-53.1%	
Impairment losses on available-for-sale financial assets	0.8	1.7	2.3	0.7	41.1%	
Foreign exchange losses including losses on valuation of derivatives	11.8	3.9	14.0	10.2	-	
Others	2.3	5.3	2.7	-2.7	-49.7%	
Share of profit of associates accounted for using the equity method	1.0	1.3	-0.0	-1.3	-	
Profit before tax	158.9	-145.4	120.5	266.0	-	132.5
Income tax expenses	49.3	-2.4	37.1	39.5	-	
Net profit for the period	109.6	-143.0	83.5	226.5	-	
<% of revenue>	<6.5%>	<-8.0%>	<4.6%>	<12.7pt>		
Attributable to Owners of the Company	106.7	-145.8	80.2	225.9	-	88.0
<% of revenue>	<6.3%>	<-8.2%>	<4.4%>	<12.6pt>		<5.1%>
Total comprehensive income for the period	343.7	-180.9	-39.6	141.3	-	
<% of revenue>	<20.3%>	<-10.2%>	<-2.2%>	<8.0pt>		
Attributable to Owners of the Company	339.2	-186.6	-40.3	146.3	-	
<% of revenue>	<20.0%>	<-10.5%>	<-2.2%>	<8.3pt>		
Effective tax rate						
Japanese statutory tax rate	38.0%	35.6%	33.0%	-2.6pt		
Effective tax rate	31.0%	1.7%	30.7%	29.1pt		

\*1 Because of starting the new organizational structure and changing managerial accounting method from FY15, allocation accounts for some expenses have changed. For the purpose to compare FY14 expenses with the FY15 expenses under the same basis (underlying), amounts roughly estimated for this change are adjusted in FY14.

Amounts adjusted are + 7.1 bln yen for cost of sales, + 22.1 bln yen for SG&A expenses, and - 29.2 bln yen for R&D expenses.

\*2 Fair value adjustments of contingents considerations are included in "Others".

\*3 Expenses from reorganization, such as the consolidation of a number of sites and functions (including the potential merger or liquidation of subsidiaries) and the reduction of the workforce to build an efficient operating model.

### 3. Revenue / Product Sales

#### ◆ Revenue by Regions

(Billions of Yen)

	FY13	FY14	FY15	vs FY14	increase/ decrease
Total revenue	1,691.7	1,777.8	1,807.4	29.6	1.7%
Japan	733.9	712.8	688.1	-24.7	-3.5%
Overseas	957.8	1,065.0	1,119.3	54.3	5.1%
<% of revenue>	<56.6%>	<59.9%>	<61.9%>	<2.0pt>	
United States	352.1	426.1	514.4	88.3	20.7%
<% of revenue>	<20.8%>	<24.0%>	<28.5%>	<4.5pt>	
Europe and Canada	320.0	325.3	309.3	-16.0	-4.9%
<% of revenue>	<18.9%>	<18.3%>	<17.1%>	<-1.2pt>	
Russia/CIS	89.6	81.3	61.8	-19.5	-24.0%
<% of revenue>	<5.3%>	<4.6%>	<3.4%>	<-1.2pt>	
Latin America	81.2	85.4	68.4	-17.0	-19.9%
<% of revenue>	<4.8%>	<4.8%>	<3.8%>	<-1.0pt>	
Asia	85.4	111.4	126.0	14.5	13.1%
<% of revenue>	<5.0%>	<6.3%>	<7.0%>	<0.7pt>	
Other	29.5	35.5	39.4	3.9	11.1%
<% of revenue>	<1.7%>	<2.0%>	<2.2%>	<0.2pt>	
Royalty income and service income	86.3	87.5	56.5	-31.1	-35.5%
Japan	2.6	8.8	7.2	-1.6	-17.8%
Overseas	83.7	78.8	49.3	-29.5	-37.5%

\* Revenue amount is classified into countries or regions based on the customer location.

\*\* Effective from FY14, the Company changed the regional classification to ensure consistency with its global organizational structure (previous "North America" was divided into "United States" and "Canada", and "Canada" and previous "Europe" were integrated into "Europe and Canada"). For fair comparison purpose, the amounts reported in the periods of FY13 were modified according to the new classification.

\*\*\* Other region includes Middle East, Oceania and Africa.

#### ◆ Ethical Drugs Revenue [Consolidated]

(Billions of Yen)

	FY13	FY14	FY15	vs FY14	increase/ decrease
Net Sales in Japan	580.0	553.2	535.1	-18.2	-3.3%
Net Sales Overseas	863.3	974.3	1,057.7	83.4	8.6%
United States	318.9	394.9	495.3	100.4	25.4%
Europe and Canada	265.6	287.1	283.5	-3.6	-1.2%
Russia/CIS	89.5	79.5	61.5	-18.0	-22.7%
Latin America	80.6	80.1	66.0	-14.0	-17.5%
Asia	80.5	102.4	116.6	14.1	13.8%
Other	28.1	30.3	34.9	4.5	14.9%
Royalty income and service income	85.8	86.9	55.8	-31.1	-35.8%
Japan	2.1	8.1	6.6	-1.5	-18.7%
Overseas	83.7	78.8	49.3	-29.6	-37.5%
Total ethical drugs revenue	1,529.1	1,614.5	1,648.7	34.2	2.1%
Ratio of overseas ethical drugs revenue	61.9%	65.2%	67.1%	1.9pt	

\* Revenue amount is classified into countries or regions based on the customer location.

\*\* Effective from FY14, the Company changed the regional classification to ensure consistency with its global organizational structure (previous "North America" was divided into "United States" and "Canada", and "Canada" and previous "Europe" were integrated into "Europe and Canada"). For fair comparison purpose, the amounts reported in the periods of FY13 were modified according to the new classification.

\*\*\* Other region includes Middle East, Oceania and Africa.

#### ◆ Ethical Drugs Revenue [Emerging Markets]

(Billions of Yen)

	FY13	FY14	FY15	vs FY14	increase/ decrease
Total revenue in emerging markets	2,808.3	3,137.1	2,904.2	-232.9	-7.4%
China		552.3	659.5	107.2	19.4%
Brazil		575.6	435.4	-140.2	-24.4%
Russia		476.4	380.7	-95.7	-20.1%

\* Revenue amount includes royalty income and service income.

\*\* "Total revenue in emerging markets" includes the revenue amounts in emerging markets other than "China", "Russia" and "Brazil."

◆ Ethical Drugs: Global major products' sales \*1

(Billion JPY)

		FY14	FY15	vs. PrY	Reported Growth	Underlying Growth	FY16 Forecasts *2
Velcade	United States	110.8	131.6	20.9	18.8%	7.3%	
	Other than United States	41.9	30.4	-11.5	-27.5%	-34.7%	
	Total	152.7	162.0	9.3	6.1%	-4.2%	↘↘
Leuprorelin	Japan	57.6	53.8	-3.8	-6.5%	-6.5%	
	United States	15.9	17.3	1.4	8.9%	6.0%	
	Europe and Canada	36.4	35.3	-1.1	-3.0%	0.5%	
	Emerging Markets	14.2	18.0	3.8	27.1%	21.6%	
	Total	124.0	124.4	0.4	0.3%	0.5%	↘
Pantoprazole	United States	11.0	13.6	2.6	23.9%	15.9%	
	Europe and Canada	49.3	43.4	-5.9	-12.0%	-8.4%	
	Emerging Markets	43.4	43.7	0.3	0.7%	0.0%	
	Total	103.7	100.8	-3.0	-2.9%	-2.0%	↘
Lansoprazole	Japan	52.5	41.3	-11.3	-21.4%	-21.4%	
	United States	28.7	27.5	-1.2	-4.1%	-12.7%	
	Europe and Canada	11.7	10.5	-1.2	-9.9%	-5.5%	
	Emerging Markets	10.1	10.2	0.1	1.2%	-2.7%	
	Total	102.9	89.5	-13.4	-13.1%	-15.2%	↘↘↘
Entyvio	United States	20.1	63.1	42.9	-	192.5%	
	Europe and Canada	7.7	21.9	14.2	184.7%	-	
	Emerging Markets	0.0	1.3	1.2	-	-	
	Total	27.8	86.2	58.3	-	199.1%	↗↗↗
Candesartan	Japan	94.6	58.5	-36.1	-38.1%	-38.1%	
	United States	2.1	1.3	-0.8	-38.5%	-45.0%	
	Europe and Canada	17.7	12.5	-5.1	-29.1%	-30.8%	
	Emerging Markets	11.4	12.4	1.1	9.3%	1.9%	
	Total	125.7	84.8	-41.0	-32.6%	-33.4%	↘↘↘
Dexilant	United States	53.5	64.0	10.6	19.8%	8.6%	
	Europe and Canada	4.9	5.4	0.5	11.2%	16.7%	
	Emerging Markets	3.9	5.7	1.7	44.0%	50.1%	
	Total	62.3	75.1	12.8	20.6%	11.9%	→
Azilva	Japan	45.4	59.0	13.7	30.1%	30.1%	
	Total	45.4	59.0	13.7	30.1%	30.1%	→
Nesina	Japan	38.4	36.9	-1.5	-3.9%	-3.9%	
	United States	4.1	5.3	1.2	29.0%	16.8%	
	Europe and Canada	0.6	3.5	2.9	-	-	
	Emerging Markets	1.3	3.3	2.0	163.2%	169.8%	
	Total	44.3	48.9	4.6	10.5%	10.4%	→
Colcrys	United States	58.8	46.5	-12.4	-21.0%	-28.9%	
	Total	58.8	46.5	-12.4	-21.0%	-28.9%	→
Uloric	United States	32.6	41.8	9.2	28.4%	16.7%	
	Europe and Canada	0.6	0.7	0.1	12.5%	17.5%	
	Total	33.2	42.5	9.3	28.1%	16.7%	→
Amitiza	United States	31.9	37.2	5.3	16.5%	5.6%	
	Europe and Canada	0.0	0.1	0.1	-	-	
	Total	32.0	37.3	5.3	16.7%	5.7%	→
Adcetris	Japan	2.8	3.1	0.3	12.5%	12.5%	
	Europe and Canada	16.3	17.4	1.1	6.6%	9.5%	
	Emerging Markets	3.6	7.2	3.6	102.7%	124.9%	
	Total	22.9	27.6	4.8	20.8%	27.6%	→
Brintellix	United States	13.6	24.5	10.9	79.9%	63.7%	
	Total	13.6	24.5	10.9	79.9%	63.7%	↗↗↗
Takecab	Japan	3.2	8.4	5.2	161.0%	161.0%	
	Total	3.2	8.4	5.2	161.0%	161.0%	↗↗↗
Ninlaro	United States	-	4.0	4.0	-	-	
	Total	-	4.0	4.0	-	-	↗↗↗

\*1 Sales amount includes royalty income and service income.

\*2 FY16 Forecasts: Arrows show growth from FY15 results (reported basis).

→ ± <10% ↗ +10% ~ 20% ↗↗ +20% ~ 30% ↗↗↗ + >30% ↘ -10% ~ 20% ↘↘ -20% ~ 30% ↘↘↘ - >30%

◆ Ethical Drugs: US major products' sales (in US\$)\*

(Millions of US\$)

	FY13	FY14	FY15	vs PrY	increase/ decrease
Velcade	953	1,017	1,079	62	6.1%
Dexilant	449	488	530	42	8.6%
Entyvio	-	179	524	345	192.5%
Colcrys	520	542	386	-157	-28.9%
Uloric	266	297	347	50	16.7%
Amitiza	257	291	308	16	5.6%
Prevacid (lansoprazole)	295	254	222	-32	-12.6%
Brintellix	4	124	203	79	63.7%
Contrave	-	19	56	37	199.9%
Ninlaro	-	-	34	34	-

\*Product sales (royalty income and service income are excluded).

◆ Ethical Drugs: Japan major products' sales

(Billions JPY)

	Launched	Therapeutic Class	FY13	FY14	FY15	vs PrY	increase/ decrease
Azilva *	(12. 5)	Hypertension	25.3	45.4	59.0	13.7	30.1%
Blopress * (candesartan)	(99. 6)	Hypertension	125.8	94.6	58.5	-36.1	-38.1%
Leuplin (leuprorelin)	(92. 9)	Prostate cancer, breast cancer and endometriosis	64.5	57.6	53.8	-3.8	-6.5%
Takepron * (lansoprazole)	(92.12)	Peptic ulcers	67.6	52.5	41.3	-11.3	-21.4%
Enbrel	(05. 3)	Rheumatoid arthritis	45.4	41.2	40.8	-0.4	-0.9%
Nesina *	(10. 6)	Diabetes	38.0	38.4	36.9	-1.5	-3.9%
Lotriga	(13. 1)	Hyperlipidemia	5.2	13.2	22.3	9.1	69.0%
Vectibix	(10. 6)	Colorectal cancer	19.4	18.3	18.4	0.0	0.3%
Reminyl	(11. 3)	Alzheimer-type dementia	12.3	13.9	16.0	2.0	14.5%
Benet	(02. 5)	Osteoporosis	11.6	10.4	9.7	-0.7	-6.5%
Basen	(94. 9)	Diabetes	16.1	11.2	8.7	-2.5	-22.5%
Actos * (pioglitazone)	(99.12)	Diabetes	15.5	10.8	8.5	-2.3	-21.3%
Takecab	(15. 2)	Acid-related Diseases	-	3.2	8.4	5.2	161.0%
Rozerem	(10. 7)	Insomnia	6.0	6.6	7.4	0.8	12.4%
Adcetris	(14. 4)	Malignant Lymphoma	-	2.8	3.1	0.3	12.5%

\* The figures include the amounts of fixed dose combinations.

◆ Consumer Healthcare: Major products' sales

(Billions JPY)

	FY13	FY14	FY15	vs PrY	increase/ decrease
Alinamin tablet	19.6	20.7	25.2	4.6	22.1%
Alinamin drink	15.1	14.9	14.9	0.1	0.4%
Benza	10.4	9.7	9.8	0.2	1.7%
Biofermin	8.4	8.1	8.6	0.5	6.1%
Borraginol	4.4	4.1	4.5	0.4	8.9%



#### 4. Consolidated Statement of Financial Position

<Assets>	(Billion JPY)					
	FY12 End	FY13 End	FY14 End	FY15 End	% of Total	vs. FY14 End
Total non-current assets	2,821.2	2,976.6	2,776.1	2,450.3	64.1%	-325.8
Property, plant and equipment	546.8	542.3	526.2	551.9	14.4%	25.8
Acquisition cost	1,109.0	1,167.7	1,177.1	1,223.8		46.8
Accumulated depreciation and impairment losses	-562.2	-625.4	-650.9	-671.9		-21.0
Goodwill	714.0	814.7	821.9	779.3	20.4%	-42.6
Intangible assets	1,095.8	1,135.6	939.4	743.1	19.4%	-196.3
Investment property	36.7	32.1	30.2	26.6	0.7%	-3.6
Investments accounted for using the equity method	9.2	10.0	10.4	10.0	0.3%	-0.4
Other financial assets	211.8	192.8	241.3	149.5	3.9%	-91.8
Investment securities	160.3	141.6	159.7	132.1		-27.6
Other non-current assets	27.5	40.8	52.2	19.0	0.5%	-33.2
Prepaid pension costs	23.3	35.8	49.0	16.9		-32.2
Deferred tax assets	179.4	208.4	154.5	170.8	4.5%	16.3
Total current assets	1,231.4	1,592.5	1,520.1	1,373.8	35.9%	-146.3
Inventories	229.3	254.3	262.4	254.0	6.6%	-8.3
Trade and other receivables	375.0	430.6	444.7	415.4	10.9%	-29.3
Other financial assets	16.2	185.0	61.3	108.6	2.8%	47.3
Income tax recoverables	12.0	12.0	22.1	15.2	0.4%	-7.0
Other current assets	49.3	43.5	63.2	64.1	1.7%	0.9
Cash and cash equivalents	545.6	666.0	652.1	451.4	11.8%	-200.7
Assets held for sale	4.0	1.0	14.2	65.0	1.7%	50.8
Total Assets	4,052.6	4,569.1	4,296.2	3,824.1	100.0%	-472.1

<Liabilities and equity>

	(Billion JPY)					
	FY12 End	FY13 End	FY14 End	FY15 End	% of Total	vs. FY14 End
Total liabilities	1,714.3	2,028.5	2,090.0	1,812.9	47.4%	-277.1
Total non-current liabilities	1,080.4	1,225.8	1,073.2	955.7	25.0%	-117.5
Bonds	471.3	463.3	419.4	179.8	4.7%	-239.7
Long-term loans	111.3	241.3	210.0	360.0	9.4%	150.0
Other financial liabilities	96.4	110.1	70.1	102.1	2.7%	32.0
Retirement benefit liabilities	66.6	76.5	91.7	84.9	2.2%	-6.8
Provisions	21.8	14.4	47.1	34.4	0.9%	-12.7
Other non-current liabilities	41.1	39.6	78.8	71.0	1.9%	-7.7
Deferred tax liabilities	271.8	280.6	156.1	123.5	3.2%	-32.7
Total current liabilities	633.8	802.8	1,016.8	857.2	22.4%	-159.6
Bonds	-	154.1	70.0	228.5	6.0%	158.5
Short-term loans	1.9	1.3	30.0	-	0.0%	-30.0
Trade and other payables	169.9	184.9	170.8	191.1	5.0%	20.3
Other financial liabilities	38.6	48.8	42.1	37.2	1.0%	-4.9
Income tax payables	129.4	52.3	41.1	43.1	1.1%	2.1
Provisions	100.8	125.3	418.6	115.3	3.0%	-303.2
Other current liabilities	193.3	236.0	238.5	226.9	5.9%	-11.6
Liability held-for-sale	-	-	5.8	15.1	0.4%	9.3
Total equity	2,338.3	2,540.6	2,206.2	2,011.2	52.6%	-195.0
Share capital	63.5	63.6	64.0	64.8		0.7
Capital surplus	40.3	39.9	59.6	68.8		9.3
Treasury shares	-0.6	-0.6	-18.2	-36.0		-17.8
Retained earnings	1,927.8	1,901.3	1,601.3	1,523.1		-78.2
Other components of equity	243.1	466.6	430.3	327.9		-102.4
Equity attributable to owners of the company	2,274.1	2,470.7	2,137.0	1,948.7		-188.4
Non-controlling interests	64.2	69.9	69.1	62.5		-6.6
Total liabilities and equity	4,052.6	4,569.1	4,296.2	3,824.1	100.0%	-472.1

5. Consolidated Statement of Cash Flows

	(Billion JPY)				
	FY12	FY13	FY14	FY15	vs. PrY
Net cash from (used in) operating activities	332.6	148.7	182.5	25.5	-157.0
Net cash from (used in) investing activities	-131.1	-154.1	91.3	-71.2	-162.6
Net cash from (used in) financing activities	-152.2	96.5	-301.0	-124.8	176.2
Net increase in cash and cash equivalents	49.3	91.2	-27.1	-170.6	-143.4
Cash and cash equivalents at beginning of year	454.2	545.6	666.0	655.2	-10.8
Effect of movements in exchange rates on cash and cash equivalents	42.0	29.3	16.3	-33.3	-49.6
Cash and cash equivalents at end of year	545.6	666.0	655.2	451.4	-203.8

## 6. Segment Information

	(Billions of Yen)					
	FY13	FY14	FY15	vs. FY14	increase/ decrease	FY16 Forecasts
Revenue	1,691.7	1,777.8	1,807.4	29.6	1.7%	1,720.0
Ethical drugs	1,529.1	1,614.5	1,648.7	34.2	2.1%	
Japan	582.1	561.3	541.7	-19.7	-3.5%	
Overseas	947.0	1,053.2	1,107.0	53.8	5.1%	
Consumer healthcare	72.9	73.6	80.1	6.5	8.9%	
Others	89.8	89.7	78.6	-11.1	-12.4%	
Operating Profit	139.3	-129.3	130.8	260.1	-	135.0
Ethical drugs	112.1	-178.9	102.8	281.7	-	
<% of Ethical drugs revenue>	<7.3%>	<-11.1%>	<6.2%>	<17.3pt>		
Consumer healthcare	16.4	17.2	18.9	1.7	10.0%	
<% of Consumer healthcare revenue>	<22.5%>	<23.4%>	<23.6%>	<0.2pt>		
Others	10.8	32.4	9.1	-23.4	-72.0%	
<% of Others revenue>	<12.0%>	<36.2%>	<11.5%>	<-24.6pt>		

## 7. Capital expenditure, depreciation and amortization and impairment losses

	(Billions of Yen)					
	FY13	FY14	FY15	vs. FY14	increase/ decrease	FY16 Forecasts
Capital expenditures	99.4	101.6	136.8	35.3	34.8%	175.0
Tangible assets*	43.9	53.7	94.0	40.3	75.2%	
Intangible assets	55.5	47.9	42.8	-5.1	-10.5%	
Depreciation and amortization	187.3	191.6	181.2	-10.3	-5.4%	
Depreciation of tangible assets*	59.3	58.7	53.4	-5.3	-9.0%	
Amortization of intangible assets	127.9	132.9	127.8	-5.1	-3.8%	
Amortization associated with products	120.1	123.2	118.7	-4.5	-3.6%	
Impairment losses	27.5	68.4	15.2	-53.2	-77.8%	
Impairment losses associated with products	23.1	53.2	6.4	-46.8	-88.0%	
Amortization and impairment losses on intangible assets associated with products	143.2	176.4	* 125.1	-51.3	-29.1%	* 140.0

\* From fiscal 2016, amortization and impairment losses of R&D-related intangible assets, such as R&D pipeline assets and platform technology, will no longer be booked as "R&D expenses", and will be reclassified and reported under the planned new account name of "Amortization and impairment losses on intangible assets associated with products, R&D pipeline and platform technology" with a FY16 forecast of 140 billion JPY. The reclassified amount in fiscal 2015 would have been 6.6 billion JPY, making the corresponding consolidated amount to be 131.8 billion JPY.

## 8. Number of employees

	FY13 End	FY14 End	FY15 End
Total ①+②	31,225	31,328	31,168
< Overseas >	<21,671>	<21,716>	<21,877>
Ethical drugs	28,672	28,761	28,762
Consumer healthcare	461	457	500
Others	2,092	2,110	1,906
Employees working in Takeda Pharmaceutical Company Limited ①	6,578	6,780	6,780
Consolidated subsidiaries ②	24,647	24,548	24,388

\* Employees on the full time equivalent basis

## 9. Shareholders

### 【By ownership】

		FY13 End	FY14 End	FY15 End	vs. FY14 End
Japanese	No. of shareholders	313	277	291	14
Institutional Investors	No. of shares(1000)	235,353	235,524	252,537	17,013
	% of shares outstanding	29.80	29.82	31.96	2.14
Japanese	No. of shareholders	67	47	64	17
Securities Companies	No. of shares(1000)	38,582	41,794	38,448	-3,346
	% of shares outstanding	4.88	5.29	4.87	-0.43
Japanese	No. of shareholders	1,890	1,567	1,515	-52
Business Corporations	No. of shares(1000)	41,626	41,751	41,133	-619
	% of shares outstanding	5.27	5.29	5.20	-0.08
Overseas	No. of shareholders	883	891	876	-15
Institutional Investors and Others	No. of shares(1000)	223,377	255,976	248,822	-7,153
	% of shares outstanding	28.29	32.40	31.49	-0.91
Japanese	No. of shareholders	305,206	266,344	262,674	-3,670
Individual Investors and Others	No. of shares(1000)	250,612	214,742	209,197	-5,545
	% of shares outstanding	31.74	27.18	26.47	-0.71
Takeda	No. of shares(1000)	130	138	147	9
	% of shares outstanding	0.02	0.02	0.02	0.00

### 【By number of shares held each】

		FY13 End	FY14 End	FY15 End	vs. FY14 End
5,000,000~	No. of shareholders	21	25	24	-1
	No. of shares(1000)	267,568	311,874	333,589	21,716
	% of shares outstanding	33.88	39.48	42.21	2.73
1,000,000~ 4,999,999	No. of shareholders	91	82	79	-3
	No. of shares(1000)	203,000	190,704	182,566	-8,139
	% of shares outstanding	25.71	24.14	23.10	-1.04
100,000~ 999,999	No. of shareholders	273	280	266	-14
	No. of shares(1000)	85,950	88,306	79,611	-8,695
	% of shares outstanding	10.88	11.18	10.07	-1.11
10,000~ 99,999	No. of shareholders	2,472	2,126	2,091	-35
	No. of shares(1000)	50,890	44,904	43,975	-929
	% of shares outstanding	6.45	5.70	5.56	-0.14
1,000~ 9,999	No. of shareholders	63,080	52,696	51,050	-1,646
	No. of shares(1000)	126,265	106,438	103,367	-3,071
	% of shares outstanding	15.99	13.48	13.08	-0.40
100~ 999	No. of shareholders	232,953	205,140	203,532	-1,608
	No. of shares(1000)	55,762	47,466	46,955	-511
	% of shares outstanding	7.06	6.01	5.94	-0.07
Less than 99	No. of shareholders	9,470	8,778	8,379	-399
	No. of shares(1000)	247	231	221	-10
	% of shares outstanding	0.03	0.03	0.03	-0.00
Total	No. of shareholders	308,360	269,127	265,421	-3,706
	No. of shares(1000)	789,681	789,924	790,284	361

### 【10 largest shareholders】

Shareholders	FY15 End		Change from FY14 End	
	No. of shares held (1,000)	% of shares outstanding	No. of shares increase/decrease (1,000)	Previous ranking
1 Nippon Life Insurance Company	50,760	6.42	-	<1>
2 The Master Trust Bank of Japan, Ltd. (Trust account)	36,308	4.59	5,262	<2>
3 Japan Trustee Services Bank, Ltd. (Trust account)	33,223	4.20	6,641	<3>
4 JP Morgan Chase Bank 380055	30,670	3.88	11,329	<4>
5 Takeda Science Foundation	17,912	2.27	-	<5>
6 Barclays Securities Japan Limited	15,000	1.90	-	<6>
7 State Street Bank West Client-Treaty 505234	13,741	1.74	2,384	<8>
8 JP Morgan Chase Bank 385147	11,358	1.44	-2,023	<7>
9 Japan Trustee Services Bank, Ltd. (Trust account 7)	10,903	1.38	2,462	<11>
10 STATE STREET BANK AND TRUST COMPANY 505225	10,044	1.27	-132	<9>

## 10. Financial ratios

	FY13	FY14	FY15
<b>[Growth rates]</b>			
Revenue (%)	8.6	5.1	1.7
Operating profit (%)	114.3	-	-
Net profit (%) *	-28.2	-	-
<b>[Profitability ratios]</b>			
Gross profit margin (%) ***	71.0	70.3	70.4
Operating margin (%)	8.2	-7.3	7.2
Net margin (%) *	6.3	-8.2	4.4
Return on total assets (%) *	2.5	-3.3	2.0
Return on equity attributable to owners of the Company (ROE) (%)	4.5	-6.3	3.9
<b>[Stability ratios]</b>			
Ratio of equity attributable to owners of the Company to total assets (%)	54.1	49.7	51.0
Current ratio (%)	198.4	149.5	160.3
Non-current assets to long-term capital (%) *	80.5	86.5	84.4
<b>[Efficiency ratios]</b>			
Asset turnover (times)	0.37	0.41	0.47
Fixed-asset turnover (times)	0.57	0.64	0.74
Notes and accounts receivable turnover (times) **	4.45	4.40	4.69
<b>[Other ratios]</b>			
R&D expenses to revenue (%)	20.2	21.5	19.1
Equity attributable to owners of the Company per share (JPY)	3,130	2,719	2,487
Basic earnings per share (EPS) (JPY) *	135.10	-185.37	102.26
Growth Rate of EPS (%)	-28.2	-	-155.2
Payout ratio (%)	133.2	-	176.0
Dividend on equity attributable to owners of the Company (DOE) (%)	6.0	6.2	6.9

\* Ratios are calculated based on amounts attributable to owners of the Company.

\*\* "Notes and accounts receivable turnover" are after adjustment of outstanding balance at each fiscal year end and/or 1st half of fiscal year if the ending day falls on weekend or holiday, and to be paid on the beginning day of the following fiscal term.

\*\*\* Because of starting the new organizational structure and changing managerial accounting method from FY15, allocation accounts for some expenses have changed. For the purpose to compare FY14 expenses with the FY15 expenses under the same basis (underlying), amounts roughly estimated for this change are adjusted in FY14.

### III. Pipeline

#### 1. Development activities

This table primarily shows the indications for which we will actively pursue approval. We are also conducting additional studies of certain assets to examine their potential for use in further indications and in additional formulations. The listings in this table are limited to the US, EU and Japan, but we are also actively conducting development activities in other regions, including in Emerging Markets.

#### ■ Oncology

Development code <generic name> BRAND NAME	Drug Class (administration route)	Indications / additional formulations	Stage	
<b>TAP-144-SR</b> <leuprorelin acetate> LEUPLIN® (Jpn) LUPRON DEPOT® (US) ENANTONE®, etc. (EU)	LH-RH agonist (injection)	6-month formulation (for Prostate cancer, Premenopausal breast cancer)	Jpn	Approved (Sep '15)
<b>MLN9708</b> <ixazomib> NINLARO® (US)	Proteasome inhibitor (oral)	Relapsed or refractory multiple myeloma	US EU Jpn	Approved (Nov '15) Filed (Jul '15) P-III
		Previously untreated multiple myeloma	US EU Jpn	P-III P-III P-III
		Maintenance therapy in patients with newly diagnosed multiple myeloma following autologous stem cell transplant	US EU Jpn	P-III P-III P-III
		Maintenance therapy in patients with newly diagnosed multiple myeloma not treated with stem cell transplant	US EU Jpn	P-III P-III P-III
		Relapsed or refractory primary (AL) amyloidosis	US EU	P-III P-III
		Solid tumors	US	P-I
		<b>SGN-35</b> <brentuximab vedotin> ADCETRIS® (EU, Jpn)	CD30 monoclonal antibody-drug conjugate (injection)	Post-autologous stem cell transplant Hodgkin lymphoma Relapsed cutaneous T-cell lymphoma Front line Hodgkin lymphoma Front line mature T-cell lymphoma
<b>AMG 386</b> <trebananib>	Anti-angiopoietin peptibody (injection)	Ovarian cancer	Jpn	P-III
<b>MLN8237</b> <alisertib>	Aurora A kinase inhibitor (oral)	Small cell lung cancer	US EU	P-II(b) P-II(b)
<b>TAK-228</b> <- - >	mTORC1/2 inhibitor (oral)	Breast cancer	US EU	P-II(b) P-II(b)
		Renal cancer	US	P-II(b)
		Endometrial cancer	US	P-II(b)
<b>TAK-385</b> <relugolix>	LH-RH antagonist (oral)	Prostate cancer	US EU Jpn	P-II(b) P-II(b) P-I
		High risk myelodysplastic syndromes	US EU	P-II(a) P-II(a)
		Solid tumors	-	P-I
<b>TAK-117</b> <- - >	PI3Kα isoform inhibitor (oral)	Non-small cell lung cancer	US EU	P-I/II P-I/II
		Gastric cancer	-	P-I
<b>TAK-243</b> <- - >	UAE inhibitor (injection)	Solid tumors	-	P-I
<b>TAK-580</b> <- - >	pan-Raf kinase inhibitor (oral)	Solid tumors	-	P-I
<b>TAK-659</b> <- - >	SYK kinase inhibitor (oral)	Solid tumors, Hematologic malignancies	-	P-I
<b>TAK-931</b> <- - >	CDC7 inhibitor (oral)	Solid tumors	-	P-I

## ■ Gastroenterology

Development code <generic name> BRAND NAME	Drug Class (administration route)	Indications / additional formulations	Stage	
TAK-390MR <dexlansoprazole> DEXILANT® (US, EU)	Proton pump inhibitor (oral)	Orally disintegrating tablet (for Acid-related diseases)	US	Approved (Jan '16)
		Acid-related diseases in adolescents	US	Filed (Sep '15)
			EU	Filed (Sep '15)
MLN0002 <vedolizumab> ENTYVIO® (US, EU)	Humanized monoclonal antibody against α4β7 integrin (injection)	Ulcerative colitis	Jpn	P-III
		Crohn's disease	Jpn	P-III
		Subcutaneous fomulation (for Ulcerative colitis, Crohn's disease)	US	P-III
			EU	P-III
Jpn	P-III			
	<lubiprostone> AMITIZA® (US)	Chloride channel activator (oral)	New formulation	US
Pediatric functional constipation			US	P-III
TAK-828 <->	RORyt inverse agonist (oral)	Crohn's disease	-	P-I

## ■ CNS

Development code <generic name> BRAND NAME	Drug Class (administration route)	Indications / additional formulations	Stage	
<glatiramer acetate> COPAXONE® (Jpn)	Immunomodulator (injection)	Relapse prevention of multiple sclerosis	Jpn	Approved (Sep '15)
Lu AA21004 <vortioxetine> BRINTELLIX® (US)* <sup>1</sup>	Multimodal anti-depressant (oral)	Addition of clinical data to the product label regarding the effect of vortioxetine on certain aspects of cognitive function in adults with Major Depressive Disorder	US	FDA Complete Response Letter (Mar '16)
		Major depressive disorder	Jpn	P-III
		Attention Deficit Hyperactivity Disorder (ADHD) in adult patients	US	P-II(a)
AD-4833/TOMM40	Insulin sensitizer (oral) / Biomarker assay	Delay of onset of mild cognitive impairment due to Alzheimer's disease	US EU	P-III P-III
TVP-1012* <sup>2</sup> <rasagiline>	Monoamine oxidase B (MAO-B) inhibitor (oral)	Parkinson's disease	Jpn	P-III
TAK-063 <->	PDE10A inhibitor (oral)	Schizophrenia	US	P-II(a)
TAK-058 <->	5-HT3 receptor antagonist (oral)	Schizophrenia, especially cognitive impairment associated with schizophrenia	-	P-I
TAK-653 <->	AMPA receptor potentiator (oral)	Psychiatric disorders, Neurological diseases	-	P-I
TAK-831 <->	D-amino acid oxidase (DAAO) inhibitor (oral)	Cerebellar ataxia, Negative symptoms and/or cognitive impairment associated with schizophrenia	-	P-I
TAK-915 <->	PDE2A inhibitor (oral)	Negative symptoms and/or cognitive impairment associated with schizophrenia	-	P-I
TAK-935 <->	CH24H inhibitor (oral)	Epilepsy	-	P-I

\*1 BRINTELLIX® will be marketed in the United States under the new name TRINTELLIX starting in June of 2016.

\*2 Brand name in Teva territories: AZILECT®



## ■ Vaccines

Development code BRAND NAME	Type of vaccine (administration route)	Indications / additional formulations	Stage	
<b>TAK-816</b> VAXEM Hib® (Jpn)	Hib vaccine (injection)	Prevention of infectious disease caused by Haemophilus influenzae type b (Hib)	Jpn	Approved (Jan '16)
<b>TAK-003</b>	Tetravalent dengue vaccine (injection)	Prevention of dengue fever caused by dengue virus	-	P-II(b)
<b>TAK-214</b>	Norovirus vaccine (injection)	Prevention of acute gastroenteritis (AGE) caused by norovirus	-	P-II(b)
<b>TAK-850</b>	Seasonal influenza vaccine (injection)	Prevention of influenza disease caused by influenza virus subtype A and B contained in the vaccine	Jpn	P-II(a)
<b>TAK-021</b>	EV71 vaccine (injection)	Prevention of hand, foot and mouth disease caused by enterovirus 71	-	P-I

## ■ Specialty CV

Development code <generic name> BRAND NAME	Drug Class (administration route)	Indications / additional formulations	Stage	
<b>TAK-272</b> <- ->	Direct renin inhibitor (oral)	Early stage diabetic nephropathy	Jpn	P-II(b)

## ■ Others

Development code <generic name> BRAND NAME	Drug Class (administration route)	Indications / additional formulations	Stage	
<b>SYR-322</b> <alogliptin> NESINA® (US, Jpn) VIPIDIA® (EU)	DPP-4 inhibitor (oral)	Fixed-dose combination with metformin (for Type 2 diabetes)	Jpn	Filed (Sep '15)
<febuxostat XR> ULORIC® (US)	Non-purine, selective xanthine oxidase inhibitor (oral)	Extended-release formulation (for Hyperuricemia)	US	P-III
<b>TAK-536</b> <azilsartan> AZILVA® (Jpn)	Angiotensin II receptor blocker (oral)	Fixed-dose combination with amlodipine and hydrochlorothiazide (for Hypertension)	Jpn	P-III
<b>TAK-385</b> <relugolix>	LH-RH antagonist (oral)	Uterine fibroids	Jpn	P-III
		Endometriosis	Jpn	P-II(b)
<b>NE-58095NF</b> <risedronate> BENET® (Jpn)	Bone resorption inhibitor (oral)	Additional formulation; change of the dosage and administration (for Osteoporosis)	Jpn	P-II/III
<b>MT203</b> <namilumab>	GM-CSF monoclonal antibody (injection)	Psoriasis	EU	P-II(b)
		Rheumatoid arthritis	EU	P-II(b)
			Jpn	P-II(a)
<b>TAK-020</b> <- ->	Bruton's tyrosine kinase inhibitor (oral)	Rheumatoid arthritis	-	P-I
<b>TAK-079</b> <- ->	Cytolytic monoclonal antibody (injection)	Rheumatoid arthritis, Systemic lupus erythematosus	-	P-I
<b>AMG 403</b> <fulranumab>	Human monoclonal antibody against human Nerve Growth Factor (NGF) (injection)	Pain	Jpn	P-I

■ Recent progress in stage [Progress in stage disclosed since release of FY2014 results (May 15th, 2015)]

Development code <generic name>	Indications / additional formulations	Country/Region	Progress in stage
<glatiramer acetate>	Relapse prevention of multiple sclerosis	Jpn	Approved (Sep '15)
<b>TAP-144-SR</b> <leuprorelin acetate>	6-month formulation (for Prostate cancer, Premenopausal breast cancer)	Jpn	Approved (Sep '15)
<b>MLN9708</b> <ixazomib>	Relapsed or refractory multiple myeloma	US	Approved (Nov '15)
<b>TAK-390MR</b> <dexlansoprazole>	Orally disintegrating tablet (for Acid-related diseases)	US	Approved (Jan '16)
<b>TAK-816</b>	Prevention of infectious disease caused by Haemophilus influenzae type b (Hib)	Jpn	Approved (Jan '16)
<b>MLN9708</b> <ixazomib>	Relapsed or refractory multiple myeloma	EU	Filed (Jul '15)
<b>TAK-390MR</b> <dexlansoprazole>	Acid-related diseases in adolescents	US, EU	Filed (Sep '15)
<b>SYR-322</b> <alogliptin>	Fixed-dose combination with metformin (for Type 2 diabetes)	Jpn	Filed (Sep '15)
<b>MLN0002</b> <vedolizumab>	Subcutaneous fomulation (for Ulcerative colitis, Crohn's disease)	US, EU, Jpn	P-III
<b>TAK-228</b> <->	Renal cancer	US	P-II(b)
<b>TAK-228</b> <->	Endometrial cancer	US	P-II(b)
<b>TAK-063</b> <->	Schizophrenia	US	P-II(a)
<b>TAK-850</b>	Prevention of influenza disease caused by influenza virus subtype A and B contained in the vaccine	Jpn	P-II(a)
<b>TAK-924</b> <pevonedistat>	High risk myelodysplastic syndromes	US, EU	P-II(a)
<b>MT203</b> <namilumab>	Rheumatoid arthritis	Jpn	P-II(a)
<b>TAK-117</b> <->	Non small cell lung cancer	US, EU	P-I/II
<b>TAK-653</b> <->	Psychiatric disorders, Neurological diseases	-	P-I
<b>TAK-831</b> <->	Cerebellar ataxia, Negative symptoms and/or cognitive impairment associated with schizophrenia	-	P-I
<b>TAK-915</b> <->	Negative symptoms and/or cognitive impairment associated with schizophrenia	-	P-I
<b>Lu AA21004</b> <vortioxetine>	Addition of clinical data to the product label regarding the effect of vortioxetine on certain aspects of cognitive function in adults with Major Depressive Disorder	US	FDA Complete Response Letter (Mar '16)
<b>TAK-385</b> <relugolix>	Uterine fibroids	Jpn	P-III
<b>TAK-828</b> <->	Crohn's disease	-	P-I
<b>TAK-931</b> <->	Solid tumors	-	P-I

Progress in stage disclosed since the announcement of FY2015 Q3 results (February 3<sup>rd</sup>, 2016) are listed under the bold dividing line

■ **Discontinued projects [Discontinuation disclosed since release of FY2014 results (May 15th, 2015)]**

Development code <generic name>	Indications (Stage)	Reason
<b>Lu AA21004</b> <vortioxetine>	Generalized anxiety disorder (US P-III)	Discontinued due to re-evaluation of the lifecycle management development program.
<b>TAK-114</b> <->	Ulcerative colitis (US, EU P-II)	Potential for a better product profile with a similar candidate compound.
<b>TAK-264</b> <->	Gastric cancer, Pancreatic cancer (US, EU P-II)	Development terminated due to lack of efficacy.
<b>TAK-137</b> <->	Psychiatric disorders, Neurological diseases (P-I)	Pharmacokinetic variability led to decrease in safety margin.
<b>TAK-272</b> <->	Hypertension (P-I)	Reconsideration of the development program for TAK-272.
<b>TAK-733</b> <->	Solid tumors (P-I)	Development terminated based on a strategic portfolio decision.
<b>Lu AA24530</b> <->	Major depressive disorder, Generalized anxiety disorder (P-I)	Lu AA24530 was investigated for major depression but has not been in active clinical development since 2009, and following the success of Brintellix (vortioxetine), it has been decided to discontinue further development.
<b>TAK-648</b> <->	Diabetic nephropathy (P-I)	Development terminated based on a strategic portfolio decision.

Discontinued projects disclosed since the announcement of FY2015 Q3 results (February 3<sup>rd</sup>, 2016) are listed under the bold dividing line

■ **Revised collaboration agreement [Revision disclosed since release of FY2014 results (May 15th, 2015)]**

Development code <generic name>	Indications (Stage)	Reason
<b>TAK-233</b> <->	Women's health (P-I)	Takeda has granted an exclusive license to Outpost Medicine for the worldwide development and commercialization rights to TAK-233. Although a promising therapeutic, TAK-233 lay outside of Takeda's core therapeutic areas of focus, and therefore Takeda looked for an opportunity to out-license the asset so it could continue to be studied and developed.

■ **Clinical study protocol summaries**

All clinical study protocol summaries are disclosed on the English-language web-site (<http://www.takeda.com/c-t/>) and all clinical study protocol information in the Japanese-language is disclosed on the Japanese-language web-site (<http://www.takeda.co.jp/c-t/>).

We anticipate that this disclosure assure transparency of information on the clinical trials for the benefit of healthcare professionals, their patients and other stakeholders, which we believe will contribute to the appropriate use of Takeda's products worldwide.

## 2. Research Activities

### ■ Main joint research activities

#### Oncology

Partner	Country	Research subject	Schedule
Seattle Genetics	US	Antibody-Drug Conjugate technology	Mar '09 -
Mersana Therapeutics	US	Antibody-Drug Conjugate technology	Apr '14 -
ImmunoGen, Inc.	US	Antibody-Drug Conjugate technology	Mar '15 -
National Cancer Center of Japan	Japan	A partnership to develop basic research to clinical development by promoting exchanges among researchers, physicians, and others engaged in anti-cancer drug discovery and cancer biology research	Apr '15 - Apr '18

#### Gastroenterology

Partner	Country	Research subject	Schedule
Cour Pharmaceutical Development Company	US	Immune modulating therapies for the potential treatment of celiac disease and other gastrointestinal diseases, utilizing Cour's Tolerizing Immune Modifying nanoParticle (TIMP) platform	Dec '15 -
Enterome	France	Microbiome targets thought to play crucial roles in gastrointestinal disorders, including inflammatory bowel diseases (e.g. ulcerative colitis) and motility disorders (e.g. irritable bowel syndrome).	Jan '16 -
enGene	Canada	Novel therapies for specialty gastrointestinal (GI) diseases using enGene's "Gene Pill" gene delivery platform	Jan '16 -

#### CNS

Partner	Country	Research subject	Schedule
Zinfandel Pharmaceuticals	US	Alzheimer's Disease Biomarker TOMM40	Dec '10 -
Kyoto University	Japan	Treatments for obesity and schizophrenia based on CNS control	Jan '11 - Mar '16
NsGene	US	Encapsulated cell therapies for the potential treatment of Parkinson's disease	Jan '16 -

#### Other / Multiple Therapeutic Area

Partner	Country	Research subject	Schedule
Tri-Institutional Therapeutics Discovery Institute	US	Collaboration of academic institutions and industry to more effectively develop innovative treatments and therapies	Oct '13 - Jun '17
Trianni, Inc.	US	Trianni's transgenic mouse platform to identify fully human monoclonal antibodies against disease targets in all therapeutic areas	Mar '14 -
MacroGenics	US	Product candidates that will be directed against jointly selected pairs of molecular targets and using MacroGenics' Dual-Affinity Re-Targeting (DART®) proprietary platform.	Sep '14 -
Keio University, Niigata University	Japan	The search for and functional analysis of disease-related RNA-binding proteins, that may lead to treatments in the areas such as CNS and oncology.	Mar '15 - Mar '18
Center for iPS Cell Research Application (CiRA), Kyoto University	Japan	Clinical applications of iPS cells in areas such as heart failure, diabetes mellitus, neuro-psychiatric disorders and cancer	Apr '15 - Mar '25
Gencia LLC	US	Mitochondrial Associated Glucocorticoid Receptors (MAGR) agonists for potential use primarily in hematological and inflammatory diseases	Aug '15 -

